



- (51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 47/68* (2017.01)
- (21) International Application Number:
PCT/US2024/059071
- (22) International Filing Date:
07 December 2024 (07.12.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|-------------------------------|----|
| 63/608,173 | 08 December 2023 (08.12.2023) | US |
| 63/609,776 | 13 December 2023 (13.12.2023) | US |
| 63/566,200 | 15 March 2024 (15.03.2024) | US |
| 63/566,201 | 15 March 2024 (15.03.2024) | US |
| 63/724,852 | 25 November 2024 (25.11.2024) | US |
| 63/724,854 | 25 November 2024 (25.11.2024) | US |
- (71) Applicant: AARVIK THERAPEUTICS, INC. [US/US];
31363 Medallion Drive, Hayward, California 94544 (US).

- (72) Inventors; and
(71) Applicants: JUNUTULA, Jagath R. [US/US]; 31363 Medallion Drive, Hayward, California 94544 (US). BLAZ-ER, Levi L. [US/CA]; 31363 Medallion Drive, Hayward, California 94544 (US). ADAMS, Jarrett [CA/CA]; 31363 Medallion Drive, Hayward, California 94544 (US). BHAKTA, Sunil [US/US]; 31363 Medallion Drive, Hayward, California 94544 (US). SIDHU, Sachdev Singh [CA/CA]; 31363 Medallion Drive, Hayward, California 94544 (US).
- (74) Agent: STORELLA, John R.; Storella & Witt, LLP, 2625 Alcatraz Ave. #197, Berkeley, California 94705 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) Title: ENGINEERED ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE




FIG. 2

(57) Abstract: Provided herein are tetravalent antibodies and immunoconjugates in which the antibodies are conjugated with a payload. The antibodies can comprise a number of different architectures in which paratopes, formed as, for example, Fabs or diabolies, are positioned relative to each other and to an Fc region. Methods of making and using the aforementioned antibodies and immunoconjugates are also provided.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*